

Message

---

**From:** Pratt, Margaret [pratt.margaret@epa.gov]  
**Sent:** 3/9/2016 7:46:54 PM  
**To:** Newhouse, Kathleen [Newhouse.Kathleen@epa.gov]  
**CC:** Hogan, Karen [Hogan.Karen@epa.gov]  
**Subject:** FW: New bioavailability of PAHs article  
**Attachments:** acs.est.pdf

Hi Kathleen,

Glad you were able to join us today, and thanks again for forwarding that spreadsheet. I have some newer notes that I intend to organize that way this morning, but had connection issues from home this morning (need to do AWL more often, I suppose).

Attached is a newly available article entitled "Oral Bioavailability, Bioaccessibility, and Dermal Absorption of PAHs from Soil — State of the Science". It was forwarded for review late last week by a member of a workgroup focusing on TCDD and PAH bioavailability. I haven't looked it over thoroughly, but it seems pretty relevant.

Finally, Stuart Yuspa is the the NCI scientist/lab chief I mentioned. Years ago he and Miriam Poirier did more collaborative work on PAH exposure and skin cancer. More recently Stu has focused on using rodent skin cancer models and Mimi's focus went in the direction of DNA-binding carcinogens such as PAHs, tamoxifen, as well as AZT/anti-retroviral drugs. <https://ccr.cancer.gov/Laboratory-of-Cancer-Biology-and-Genetics/stuart-h-yuspa>

See you at SOT?

Cheers,  
Margaret